Novartis’ Zykadia and AbbVie’s Maviret get positive recommendations More: NICE nods for AbbVie in hep C and Novartis in lung cancer Source: News
read more37 percent of patients had PFS for a year with Tecentriq and Avastin plus chemotherapy More: Roche lung cancer combo doubles PFS rates Source: News
read moreCould lead to “unparalleled” advances in the field More: More than 2,000 immune-oncology drugs now in development Source: News
read moreMore results may be out from a closely watched trial of Roche’s Tecentriq in lung cancer, but industry watchers still don’t have many of the answers they’re looking for. More: Roche's latest Tecentriq results shed little light on the lung
read moreAll these years after its initial approval, Pfizer’s little blue pill Viagra is coming to the end of its patent life. Still, the company has plans to keep its key med churning. More: Pfizer's legendary Viagra finally set to face
read moreOn Thursday, Roche unveiled positive results from its first-line lung-cancer combo trial—but those results raised more questions than they provided answers. More: Can Roche's Tecentriq leapfrog rival meds in lung cancer? Jury's still out Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals